| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
17,121 |
15,747 |
$1.08M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
7,136 |
6,652 |
$407K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
740 |
715 |
$57K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,425 |
3,149 |
$43K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
6,648 |
6,442 |
$42K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
65 |
64 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
856 |
804 |
$5K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
390 |
381 |
$4K |
| 99000 |
|
719 |
698 |
$1K |
| 94760 |
|
746 |
726 |
$232.31 |
| 81002 |
|
174 |
170 |
$186.91 |
| 69210 |
|
12 |
12 |
$92.65 |
| 71046 |
Radiologic examination, chest; 2 views |
33 |
31 |
$58.95 |
| 81003 |
|
28 |
27 |
$28.35 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
475 |
466 |
$13.28 |
| 94761 |
|
128 |
127 |
$5.68 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
86 |
83 |
$3.99 |
| 3210F |
|
33 |
31 |
$0.00 |